Abstract
SR146131 is a potent and selective agonist at cholecystokinin subtype 1 (CCK1) receptors in vitro. The present study evaluates the activity of the compound in vivo. SR146131 completely inhibited gastric and gallbladder emptying in mice (ED50 of 66 and 2.7 μg/kg p.o., respectively). SR146131 dose dependently reduced food intake in fasted rats (from 0.1 mg/kg p.o.), in nonfasted rats in which food intake had been highly stimulated by the administration of neuropeptide Y (1–36) (from 0.3 mg/kg p.o.), in fasted gerbils (from 0.1 mg/kg p.o.), and in marmosets maintained on a restricted diet (from 3 mg/kg p.o.). SR146131 (10 mg/kg p.o.) also increased the number of Fos-positive cells in the hypothalamic paraventricular nucleus of rats. Locomotor activity of mice was reduced by orally administered SR146131 (from 0.3 mg/kg p.o.). When administered intrastriatally, SR146131 elicited contralateral turning behavior in mice. Furthermore, orally administered SR146131 (0.3–10 mg/kg), also reduced the levels of cerebellar cyclic GMP. Finally, SR146131 (0.1 μg/kg to 1 mg/kg, p.o.) significantly and dose dependently antagonized fluphenazine-induced mouth movements in rats. The CCK1 antagonist SR27897B prevented all the effects of SR146131. Conversely, SR146131 was unable to elicit any agonist or antagonist effects in a model of CCK2 receptor stimulation in vivo. SR146131 is a very potent and selective nonpeptide CCK1 agonist in vivo. SR146131 is more potent than any other CCK1 agonists reported to date. Because pharmacodynamic studies suggest that SR146131 should have a high absolute bioavailability, it may be a promising drug for the treatment of eating and motor disorders in humans.
Footnotes
-
Send reprint requests to: Dr. Eric Bignon, Sanofi Recherche, Exploratory Research Department, 195 route d’Espagne, 31036 Toulouse Cedex, France. E-mail: eric.bignon{at}sanofi.com
-
↵1 Current address: Sanofi Recherche, 371 rue du Professeur Joseph Blayac, 34184 Montpellier Cedex, France.
-
↵2 Current address: Sanofi Midy Research Center, via G.B. Piranesi, 38, 20137, Milan, Italy.
- Abbreviations:
- CCK
- cholecystokinin
- CCK8S
- sulfated cholecystokinin octapeptide
- NPY
- neuropeptide Y
- Received October 14, 1998.
- Accepted December 23, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|